A Double-Blind, Randomized Controlled Trial of Hydroxychloroquine for Cognitive Dysfunction and Inflammatory Biomarkers in Systemic Lupus Erythematosus Patients in Indonesia

A Double-Blind, Randomized Controlled Trial of Hydroxychloroquine for Cognitive Dysfunction and Inflammatory Biomarkers in Systemic Lupus Erythematosus Patients in Indonesia

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune condition characterized by persistent, chronic inflammation that damages organ tissue. One of the symptoms that is often found in SLE is cognitive dysfunction. Hydroxychloroquine is recommended for the treatment of all levels of SLE. Th...

Bibliografski detalji
Glavni autori:	Bantar Suntoko, Suharyo Hadisaputro, Handono Kalim, Suyanto Hadi, Ika Vemilia Warlisti
Format:	Članak
Jezik:	English
Izdano:	Secretariat of The Indonesian Biomedical Journal 2023-08-01
Serija:	Indonesian Biomedical Journal
Online pristup:	https://inabj.org/index.php/ibj/article/view/2504

Slični predmeti

Relationship Between Disease Activity, Levels of IFN-a, IL-4, IL-6, and Anti-NMDA to Cognitive Dysfunction (MoCA-INA Score) in Systemic Lupus Erythematosus (SLE) Patients with Cognitive Dysfunction
od: Bantar Suntoko, i dr.
Izdano: (2023-07-01)

Diagnosis and Management of Cognitive Dysfunction In Systemic Lupus Erythematosus Patients
od: Perdana Aditya Rahman, i dr.
Izdano: (2022-05-01)

Hyperuricemia and Pro Inflammatory Cytokine (IL-1Î², IL-6, and TNF-Î±)
od: Suyanto Hadi, i dr.
Izdano: (2018-02-01)

Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus
od: Liu Peng-Cheng, i dr.
Izdano: (2024-05-01)

Periodontal Tissue Condition on Systemic Lupus Erythematosus Patients: A Clinical Study
od: Nanda Rachmad Putra Gofur, i dr.
Izdano: (2022-03-01)

Hydroxychloroquine-induced retinal toxicity in systemic lupus erythematosus
od: Kisha D Piggott, i dr.
Izdano: (2018-01-01)

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
od: Alina Dima, i dr.
Izdano: (2022-02-01)

Periodontal Comparison on Systemic Lupus Erythematosus Patients and Healthy Subjects: A Cross-Sectional Study
od: Nanda Rachmad Putra Gofur, i dr.
Izdano: (2021-11-01)

Periodontitis is associated with disease severity and anti-double stranded DNA antibody and interferon-gamma levels in patients with systemic lupus erythematosus
od: Nanda R.P. Gofur, MS, i dr.
Izdano: (2019-12-01)

Association between senescence of T cells and disease activity in patients with systemic lupus erythematosus
od: Handono Kalim, i dr.
Izdano: (2021-10-01)

New onset bullous lupus erythematosus in a systemic lupus erythematosus patient after initiation of hydroxychloroquin
od: Chanchal Gera, i dr.
Izdano: (2014-01-01)

Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough?
od: Guillermo Ruiz-Irastorza, i dr.
Izdano: (2025-02-01)

Hydroxychloroquine in systemic lupus erythematosus and psychosis. A case report
od: M. Martínez Grimal, i dr.
Izdano: (2024-04-01)

Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine
od: Z. Aouhab, i dr.
Izdano: (2019-11-01)

Multichannel perimetric alterations in systemic lupus erythematosus treated with hydroxychloroquine
od: David P. Piñero, i dr.
Izdano: (2017-04-01)

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus
od: Michele Iudici, i dr.
Izdano: (2022-03-01)

Oral Hygiene and Dental Caries Status on Systemic Lupus Erythematosus Patients: A Cross-Sectional Study
od: Nanda Rachmad Putra Gofur, i dr.
Izdano: (2022-03-01)

Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
od: Alberto Floris, i dr.
Izdano: (2018-01-01)

Hydroxychloroquine lowers the risk for Diabetes Mellitus in patients with Systemic Lupus Erythematosus
od: Dennis Levinson, i dr.
Izdano: (2022-10-01)

The phenotype of CD3–CD56bright and CD3–CD56dim natural killer cells in systemic lupus erythematosus patients and its relation to disease activity
od: Dwi Soelistyoningsih, i dr.
Izdano: (2022-08-01)

Assessment of SLEDAI score changes in systemic lupus erythematosus patients under low-dose interleukin-2 therapy: A meta-analysis
od: Dwi Soelistyoningsih, i dr.
Izdano: (2024-09-01)

S15.1 Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus
od: S Fasano, i dr.
Izdano: (2022-10-01)

The Correlation between Serum Concentration of Vitamin D with Vitamin D Receptor Expression and Disease Activity in Indonesian Patients with Systemic Lupus Erythematosus: Preliminary Study
od: Kusworini Handono, i dr.
Izdano: (2014-05-01)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
od: Ronald F van Vollenhoven, i dr.
Izdano: (2021-04-01)

Successful treatment of cardiac tamponade with systemic lupus erythematosus using belimumab and hydroxychloroquine
od: Tomoo Kise, i dr.
Izdano: (2023-01-01)

An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosus
od: Atsushi Manabe, i dr.
Izdano: (2024-04-01)

Effect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus
od: Peng-Cheng Liu, i dr.
Izdano: (2024-04-01)

Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus
od: Noël Zahr, i dr.
Izdano: (2021-03-01)

Incidental retinal vascular occlusions on hydroxychloroquine screening in patients with systemic lupus erythematosus
od: Bajwa A, i dr.
Izdano: (2015-05-01)

Hydroxychloroquine-Induced Psoriasis-form Erythroderma in a Patient with Systemic Lupus Erythematosus
od: Wen-Ming Wang, i dr.
Izdano: (2018-01-01)

Extensive discoid lupus erythematosus in a HIV patient responding to hydroxychloroquine monotherapy
od: Pradeep Vittal Bhagwat, i dr.
Izdano: (2012-01-01)

Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus
od: Mohammed Salah Eldin Abdelbaky, i dr.
Izdano: (2021-06-01)

CS-31 Safety of hydroxychloroquine withdrawal in older adults with systemic lupus erythematosus
od: Anca Askanase, i dr.
Izdano: (2018-08-01)

Oculometric biomarkers of visuomotor deficits in clinically asymptomatic patients with systemic lupus erythematosus undergoing long-term hydroxychloroquine treatment
od: Andrew R. Berneshawi, i dr.
Izdano: (2024-07-01)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
od: Peter Izmirly, i dr.
Izdano: (2021-04-01)

Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine
od: John P. O’Laughlin, i dr.
Izdano: (2016-01-01)

O9 Early pregnancy exposure to hydroxychloroquine and preterm delivery in systemic lupus erythematosus
od: Elisabet Svenungsson, i dr.
Izdano: (2024-03-01)

Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus
od: Jae-Eun Lee, i dr.
Izdano: (2023-05-01)

Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus
od: Alexander KC Leung, i dr.
Izdano: (2020-07-01)

Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study
od: Ruth Fernandez-Ruiz, i dr.
Izdano: (2020-08-01)